Evidence map›Paper›PMID 41227369›Full record

ReviewCells2025

Dysferlin and the Regulation of Ca

Robert J Bloch, Joaquin Muriel, Valeriy Lukyanenko

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. An Unbiased Drug Screen in a Drosophila Model ofInternational journal of molecular sciences · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Robert J BlochDepartment of Pharmacology and Physiology, School of Medicine, University of Maryland, 655 W. Baltimore St., Baltimore, MD 21201, USA.ORCID 0000-0002-4933-3469
Joaquin MurielDepartment of Pharmacology and Physiology, School of Medicine, University of Maryland, 655 W. Baltimore St., Baltimore, MD 21201, USA.
Valeriy LukyanenkoDepartment of Pharmacology and Physiology, School of Medicine, University of Maryland, 655 W. Baltimore St., Baltimore, MD 21201, USA.ORCID 0000-0003-2462-4603

Funding

Role of Dysferlin in T-Tubules of Skeletal MuscleR01AR064268 · NIAMS · UNIVERSITY OF MARYLAND BALTIMORE · PI BLOCH, ROBERT J · 2014 to 2018
$1.9M
C2 domain therapeutics for muscular dystrophyR01AR082469 · NIAMS · UNIVERSITY OF MARYLAND BALTIMORE · PI ROBERT J BLOCH, Noah Weisleder · 2024 to 2026
$1.6M
NIAMS NIH HHS R01 AR064268NIAMS NIH HHS R01 AR082469
6 · The paper itself

Abstract

Dysferlin is a large transmembrane protein that is mutated or absent in Limb Girdle Muscular Dystrophy Type R2 (LGMD R2). Although it may have several functions in healthy skeletal muscle, most research on dysferlin has addressed its roles in repair of the sarcolemma and in maintaining proper control of Ca

Indexed as

CalciumDysferlinMuscle, SkeletalAnimalsCalcium SignalingHomeostasisHumansMuscular Dystrophies, Limb-GirdleCalciumDysferlincouplonexcitation-contraction couplingmembrane repairRyRsarcolemma

Identifiers

PMID41227369
PMCPMC12609527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.